Prevention of heart failure in mice by an antiviral agent that inhibits type 5 cardiac adenylyl cyclase
about
Similarly potent inhibition of adenylyl cyclase by P-site inhibitors in hearts from wild type and AC5 knockout miceHD Physiology Project-Japanese efforts to promote multilevel integrative systems biology and physiome research.Isoform selectivity of adenylyl cyclase inhibitors: characterization of known and novel compoundsDevelopment of a high-throughput screening paradigm for the discovery of small-molecule modulators of adenylyl cyclase: identification of an adenylyl cyclase 2 inhibitor.Overexpression of adenylyl cyclase type 5 (AC5) confers a proarrhythmic substrate to the heartMst1 inhibition rescues β1-adrenergic cardiomyopathy by reducing myocyte necrosis and non-myocyte apoptosis rather than myocyte apoptosisInhibition of adenylyl cyclase type 5 increases longevity and healthful aging through oxidative stress protectionAdenylyl Cyclase Type 5 Deficiency Protects Against Diet-Induced Obesity and Insulin ResistanceA Food and Drug Administration-Approved Antiviral Agent that Inhibits Adenylyl Cyclase Type 5 Protects the Ischemic Heart Even When Administered after Reperfusion.Adenylyl cyclase type 5 in cardiac disease, metabolism, and aging.'Reduced malignancy as a mechanism for longevity in mice with adenylyl cyclase type 5 disruption'.Type 5 adenylyl cyclase increases oxidative stress by transcriptional regulation of manganese superoxide dismutase via the SIRT1/FoxO3a pathway.The role of Epac in the heart.Adenylyl cyclase regulation in heart failure due to myocardial infarction in rats.Chemical suppressors of mlo-mediated powdery mildew resistance.Response to Letter to the Editor on "Does Vidarabine Mediate Cardioprotection via Inhibition of AC5?".
P2860
Q27311590-52915E9D-F5E1-47BC-922F-A196AD4F7122Q33731246-06A7DD57-ED41-4B18-B11F-890CAA448C48Q34978520-52AC3A2D-5D78-4A03-B9A2-AFB83B8D92EAQ34979178-3E4ACE61-89E4-44CA-8B56-9127BA9D0A8AQ35035194-E7CA5697-40A7-4E07-B358-38F9CB45820EQ35170119-AC6A57FD-FD49-4D46-BB99-F1BCECEC89B5Q35511952-EF09513D-83F6-4ED5-A406-FBCE806F060BQ35769605-8C860B41-BD6A-4F09-BEC8-05193EF6F250Q36852542-68E45A8F-3664-4AD6-A7A8-2E810EA40507Q37054928-D860AF1D-085A-4CCA-A0E4-3BFBBDAC4C7CQ37693261-7993C3A0-C2F8-49D9-959B-0E763DEC9621Q37693302-1B9D4FB6-E121-49CC-B4F7-59EB40B77726Q38934306-B2D27C8A-87F3-480D-B870-9A0892811FA6Q43634603-75515A63-7EEE-4503-926A-D0784D26D608Q47104454-1C25B8FD-0167-4E0D-A6E6-325E13F58AFDQ51648442-67978BEB-317E-4BEB-B4D5-85B3EE407C82
P2860
Prevention of heart failure in mice by an antiviral agent that inhibits type 5 cardiac adenylyl cyclase
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Prevention of heart failure in ...... ype 5 cardiac adenylyl cyclase
@ast
Prevention of heart failure in ...... ype 5 cardiac adenylyl cyclase
@en
type
label
Prevention of heart failure in ...... ype 5 cardiac adenylyl cyclase
@ast
Prevention of heart failure in ...... ype 5 cardiac adenylyl cyclase
@en
prefLabel
Prevention of heart failure in ...... ype 5 cardiac adenylyl cyclase
@ast
Prevention of heart failure in ...... ype 5 cardiac adenylyl cyclase
@en
P2093
P2860
P1476
Prevention of heart failure in ...... ype 5 cardiac adenylyl cyclase
@en
P2093
Claudio Bravo
Dorothy E Vatner
Erdene Baljinnyam
Hongyu Qiu
Kosaku Iwatsubo
Masami Uechi
Misun Park
Mizuka Iwatsubo
Satoshi Okumura
P2860
P304
P356
10.1152/AJPHEART.00190.2012
P577
2012-04-13T00:00:00Z